Abbott Laboratories ABT faced industry-wide challenges that exerted pressure on its profit margins. Factors such as rising ...

Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests. Guidance: Abbott projects full-year 2025 ...

Q4 2024 Earnings Call Transcript January 22, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.34 EPS, expectations were $1.34. Operator: Good morning and thank ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...

For fourth-quarter fiscal 2024, Abbott projects ... quarter. The rapid and point-of-care diagnostics businesses are expected to have gained from the continued expansion of test menus and ...

Hollywood’s history is filled with legendary comedy teams, each leaving behind a unique imprint on the world of entertainment. Some, like Laurel & Hardy, shared a deep camaraderie that shone through ...

For the full calendar of 2024, Abbott recorded ... Elsewhere, in the field of rapid diagnostics, the company reported strong demand for its infectious disease tests covering the flu, strep throat ...

Welcome to Abbott’s Fourth Quarter 2024 ... Growth in the quarter was led by rapid diagnostics where excluded COVID testing sales increased 16% in the quarter. This was driven by strong demand ...

Abbott Laboratories is forecasting lower ... but the company saw increased demand for rapid flu, strep and RSV tests.